Digital Chest Tomosynthesis Possible Lung Cancer Screening Tool
Digital chest tomosynthesis (DT), a tomographic technique, may offer an alternative to CT screening. A recent study published in the Journal of Thoracic Oncology (JTO), concludes that digital chest tomosynthesis holds promise as a first-line lung cancer screening tool.
DT uses a conventional radiograph tube, a flat-panel detector, a computer-controlled tube mover, and special reconstruction algorithms to produce section images. Compared with conventional chest radiography, chest tomosynthesis improved sensitivity in the detection of CT-proven lung nodules. Although it lacks the depth resolutionof CT, tomosynthesis provides some of the benefits of CT at lower costs and radiation dosages. Furthermore, DT is less expensive than CT at approximately one-sixths of the cost of a CT.
Researchers from the Thoracic Surgery Unit and Department of Radiology at the S. Corce City Hospital in Cuneo, Italy studied assessed 1919 patients. Participants were age 45 to 75 with a smoking history of at least 20 pack years, without malignancy in the 5 years before the start of the study in December 2010. A tomosynthesis was performed at baseline and a year later.
The researchers conclude that, “the results on the use of DT in early detection of lung cancer are encouraging; the detection rate is comparable to the rates reported for low-dosage CT and is attained at a far lower cost and radiation dosage.”
The lead author of this work is IASLC Member Dr. Alberto Terzi.
Source: International Association for the Study of the Lung Cancer (IASLC).
Published on : Wed, 29 May 2013
Print as PDF
Monitor vital signs of sensitive patients with reliable, smart and intuitive technology Not available in the US Sensitive patients, like neonates, require comfortable care. With transcutaneous monitoring, you can easily keep track of the oxygenation...
The technical and clinical reference standard for all B·R·A·H·M·S PCT assays. All clinical cut-offs and algorithms were developed based on B·R·A·H·M·S PCT sensitive KRYPTOR. Homogeneous immunoassay for the quantitative d
The iLA Membrane Ventilator is an extrapulmonary ventilation system which is used primarily to remove carbon dioxide. The heart pumps blood through it as it does through a natural organ. The gas exchange takes place via a plasma-tight, heparin-coated...
XENIOS AG is a medical device company with the three brands, novalung, i-cor and medos, that run on a single XENIOS platform. This platform enables next-generation therapies for lung and heart failure. No other company except XENIOS AG is offering lung...